Jeffrey W. Sherman - 28 Aug 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Director
Signature
/s/ Beth Hecht, Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
28 Aug 2025
Net transactions value
-$21,229
Form type
4
Filing time
29 Aug 2025, 17:21:38 UTC
Previous filing
04 Jun 2025
Next filing
02 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
SHERMAN JEFFREY W Director C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO /s/ Beth Hecht, Attorney-in-Fact 29 Aug 2025 0001230482

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Options Exercise $313,286 +47,040 +22% $6.66 261,420 28 Aug 2025 Direct
transaction XERS Common Stock Sale $334,515 -42,232 -16% $7.92 219,188 28 Aug 2025 Direct F1
holding XERS Common Stock 5,400 28 Aug 2025 By: JEFFREY W SHERMAN LIVING TRUST U/A DTD 03/21/2001 F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XERS Stock Option (Right to Buy) Options Exercise $0 -47,040 -100% $0.000000 0 28 Aug 2025 Common Stock 47,040 $6.66 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.920 to $7.935, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3 On October 1, 2016, the reporting person was granted an option to purchase shares of Strongbridge Biopharma plc ("Strongbridge") which were assumed by Issuer in connection with the acquisition of Strongbridge. The options vested in full on October 5, 2021.